Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: a single-centre experience

Purpose The aim of our study was to retrospectively evaluate the feasibility and clinical benefit of cyberknife stereotactic radiosurgery (CSRS) in patients treated at Florence University for recurrent, pre-irradiated brain lesions. Materials and methods Thirteen patients were retreated with cyberkn...

Full description

Saved in:
Bibliographic Details
Published in:Radiologia medica 2014-09, Vol.119 (9), p.721-726
Main Authors: Greto, Daniela, Livi, Lorenzo, Bonomo, Pierluigi, Masi, Laura, Detti, Beatrice, Meattini, Icro, Mangoni, Monica, Doro, Raffaella, Favuzza, Virginia, Cipressi, Samantha, Iermano, Carmine, Bonucci, Ivano, Loi, Mauro, Biti, Gianpaolo
Format: Article
Language:English
Subjects:
Adult
Aged
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - secondary
Brain Neoplasms - surgery
Diagnostic Radiology
Feasibility Studies
Glioblastoma - surgery
Humans
Imaging
Interventional Radiology
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local
Neuroradiology
Radiology
Radiosurgery - adverse effects
Radiosurgery - methods
Radiotherapy
Retrospective Studies
Tomography, X-Ray Computed
Treatment Outcome
Ultrasound
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The aim of our study was to retrospectively evaluate the feasibility and clinical benefit of cyberknife stereotactic radiosurgery (CSRS) in patients treated at Florence University for recurrent, pre-irradiated brain lesions. Materials and methods Thirteen patients were retreated with cyberknife. Mean age was 47.1 years (range 33–77 years). Karnofsky performance status ranged from 60 to 100 (median 80). Eleven (84.6 %) out of 13 patients had metastatic lesions: four (36.4 %) had primary lung, three (27.2 %) had primary breast cancer and four (36.4 %) other types of solid malignancies. Two (15.4 %) out of 13 patients had recurrent of glioblastoma. Results In terms of compliance with CSRS, the majority of patients did not develop any acute side effects. However, two (15.4 %) out of 13 patients developed acute grade 2 toxicity requiring an increase of steroid medication. At the time of the last follow-up, response rates were as follows: complete response in one case (16.6 %), partial response in three (50 %) and stable disease in two (33.4 %). Conclusions Re-irradiation with CSRS is a feasible and effective option for pre-irradiated, recurrent brain lesions to obtain clinical benefit without excessive acute toxicity.
ISSN:0033-8362
1826-6983
DOI:10.1007/s11547-014-0383-2